Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice.
To examine potential interactions between leptin and the beta3 adrenergic system in the regulation of food intake, we determined the effects of treatment with a selective beta3 adrenergic receptor (AR) agonist (CL 316,243 [1 mg/kg]) on body weight, food intake, and leptin expression. Studies were carried out in C57Bl/6J and FVB male control mice as well as in mice with targeted disruption of the beta3 AR gene. These findings were correlated with measurement of the expression in hypothalamus of neuropeptide Y (NPY) and melanin concentrating hormone (MCH), two neuropeptides that may be involved in the central regulation of food intake. Treatment with CL 316,243 (1 mg/kg) for 12 or 24 h decreased leptin mRNA abundance and circulating levels to 20% of baseline in normal animals. No effect of the CL 316,243 compound was seen in mice with targeted disruption of the beta3 AR gene. Despite the failing leptin levels, beta3 agonist administration acutely suppressed food intake. Finally, the induced suppression of food intake and leptin levels occurred despite unchanged or increased hypothalamic expression of the orexigenic neuropeptides NPY and MCH. Thus, beta3 AR agonists via beta3 ARs suppress leptin levels acutely and simultaneously suppress food intake via a mechanism that operates downstream of leptin and two of its putative central targets.
Mantzoros
C S
CS
Division of Endocrinology, Beth Israel Hospital, Boston, Massachusetts, USA.
Qu
D
D
Frederich
R C
RC
Susulic
V S
VS
Lowell
B B
BB
Maratos-Flier
E
E
Flier
J S
JS
D000273:Adipose Tissue / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D004149:Dioxoles / Q000494:pharmacology*; D005215:Fasting; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology*; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D007028:Hypothalamic Hormones / Q000096:biosynthesis; D007031:Hypothalamus / Q000378:metabolism; D020738:Leptin; D008297:Male; D008543:Melanins / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D009478:Neuropeptide Y / Q000096:biosynthesis; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D010907:Pituitary Hormones / Q000096:biosynthesis; D014176:Protein Biosynthesis; D011506:Proteins / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000096:biosynthesis; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology*; D022702:Receptors, Adrenergic, beta-3; D054411:Receptors, Leptin; D012727:Sex Characteristics
D000319:Adrenergic beta-Antagonists; D000906:Antibodies; D004149:Dioxoles; D007028:Hypothalamic Hormones; D020738:Leptin; D008543:Melanins; D009478:Neuropeptide Y; D010446:Peptide Fragments; D010907:Pituitary Hormones; D011506:Proteins; D012333:RNA, Messenger; D011943:Receptors, Adrenergic, beta; D022702:Receptors, Adrenergic, beta-3; D054411:Receptors, Leptin; C515447:leptin receptor, mouse; C076126:disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate; C019463:melanin-concentrating hormone